Cell Therapeutics’ recent acquisition of Systems Medicine will not only garner CTI worldwide rights to brostallicin, a DNA minor-groove binding agent that has shown anti-tumor activity in various types of cancer, but will also enable CTI to leverage SMi’s affiliation with the Translational Genomics Research Institute to personalize treatment for brostallicin and other oncology drugs in their pipeline using PGx tools.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.